Growth and Funding EyeBio has grown through a Series A expansion to 130M and strategic partnerships, signaling strong investor backing and ample resources for scale. Sales opportunity: position complementary ophthalmology tools, contract research services, or co-development partnerships to leverage their expanded capital and collaboration appetite.

Retina Focus The company targets retinal diseases with a new generation of eye therapies, indicating a need for specialized drug delivery, diagnostic platforms, and clinical trial support in retina care. Sales opportunity: offer imaging analytics, ophthalmic instrumentation, or regulatory affairs services tailored to retinal therapeutics.

Leadership and Talent Appointment of a Chief Human Resources Officer in 2024 suggests an emphasis on scaling operations and talent. Sales opportunity: provide HR tech, performance management, or training solutions to support rapid growth and clinical development teams.

Strategic Alliances Partnerships with Ingenia and AntlerA indicate openness to collaboration on research, licensing, and clinical programs. Sales opportunity: propose alliance management, IP due diligence, or co-development frameworks and financing advisory for additional partnerships.

Publicity and Reach High-visibility funding news and coverage across outlets highlight EyeBio’s market presence and credibility in ophthalmology biotech. Sales opportunity: engage with key opinion leaders, provide market access consulting, or offer educational and symposium sponsorships to accelerate adoption of their therapies.